ACD855 / AlzeCure - LARVOL DELTA

ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics. (PubMed, Eur J Clin Pharmacol) - P1 | "The prediction proved accurate demonstrating the value of conducting a microdose study prior to ascending dose studies."

Journal • PK/PD data • Alzheimer's Disease • CNS Disorders • Depression • Psychiatry

Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept? (PubMed, Psychopharmacology (Berl)) - "Trk-PAMs could provide an interesting avenue for the development of novel therapeutics in this area."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction. (PubMed, Cells) - "To identify molecules that could potentiate neurotrophin signaling, 25,000 molecules were screened, which led to the identification of the triazinetrione derivatives ACD855 (Ponazuril) and later on ACD856, as positive allosteric modulators of tropomyosin related kinase (Trk) receptors. We have identified a novel mechanism to modulate the activity of the Trk-receptors. The identification of the positive allosteric modulators of the Trk-receptors might have implications for the treatment of Alzheimer's diseases and other diseases characterized by cognitive impairment."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • BDNF • NGF • NTRK2